Skip to main content

Research Repository

Advanced Search

All Outputs (21)

Diagnostic accuracy of autofluorescence-Raman microspectroscopy for surgical margin assessment during Mohs micrographic surgery of basal cell carcinoma (2024)
Journal Article
Boitor, R. A., Varma, S., Sharma, A., Odedra, S., Elsheikh, S., Eldib, K., …Notingher, I. (2024). Diagnostic accuracy of autofluorescence-Raman microspectroscopy for surgical margin assessment during Mohs micrographic surgery of basal cell carcinoma. British Journal of Dermatology, Article ljae196. https://doi.org/10.1093/bjd/ljae196

Background Autofluorescence (AF)–Raman microspectroscopy is a technology that can detect residual basal cell carcinoma (BCC) on the resection margin of fresh, surgically excised tissue specimens. The technology does not require tissue fixation, st... Read More about Diagnostic accuracy of autofluorescence-Raman microspectroscopy for surgical margin assessment during Mohs micrographic surgery of basal cell carcinoma.

Discontinuation of anti-tumour necrosis factor alpha treatment owing to blood test abnormalities, and cost-effectiveness of alternate blood monitoring strategies (2024)
Journal Article
Abhishek, A., Stevenson, M. D., Nakafero, G., Grainge, M. J., Evans, I., Alabas, O., …Williams, H. C. (2024). Discontinuation of anti-tumour necrosis factor alpha treatment owing to blood test abnormalities, and cost-effectiveness of alternate blood monitoring strategies. British Journal of Dermatology, 190(4), 559-564. https://doi.org/10.1093/bjd/ljad430

Background: There is no evidence base to support the use of 6-monthly monitoring blood tests for the early detection of liver, blood and renal toxicity during established anti-tumour necrosis factor alpha (TNFα) treatment. Objectives: To evaluate the... Read More about Discontinuation of anti-tumour necrosis factor alpha treatment owing to blood test abnormalities, and cost-effectiveness of alternate blood monitoring strategies.

Commentary: A comparative randomized clinical trial evaluating the efficacy and safety of tacrolimus versus hydrocortisone as a topical treatment of atopic dermatitis in children (2024)
Journal Article
Harvey, J., Stuart, B., & Williams, H. C. (2024). Commentary: A comparative randomized clinical trial evaluating the efficacy and safety of tacrolimus versus hydrocortisone as a topical treatment of atopic dermatitis in children. Frontiers in Pharmacology, 15, Article 1372259. https://doi.org/10.3389/fphar.2024.1372259

Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation (2024)
Journal Article
Abhishek, A., Grainge, M., Card, T., Williams, H. C., Taal, M. W., Aithal, G. P., …Riley, R. (2024). Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation. RMD Open, 10(1), Article e003980. https://doi.org/10.1136/rmdopen-2023-003980

Background Sulfasalazine-induced cytopenia, nephrotoxicity and hepatotoxicity is uncommon during long-term treatment. Some guidelines recommend 3 monthly monitoring blood tests indefinitely during long-term treatment while others recommend stopping m... Read More about Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation.

Cost-effectiveness of two online interventions supporting self-care for eczema for parents/carers and young people (2024)
Journal Article
Sach, T. H., Onoja, M., Clarke, H., Santer, M., Muller, I., Becque, T., …Thomas, K. S. (2024). Cost-effectiveness of two online interventions supporting self-care for eczema for parents/carers and young people. European Journal of Health Economics, https://doi.org/10.1007/s10198-023-01649-9

Objective: To estimate the cost-effectiveness of online behavioral interventions (EczemaCareOnline.org.uk) designed to support eczema self-care management for parents/carers and young people from an NHS perspective. Methods: Two within-trial economic... Read More about Cost-effectiveness of two online interventions supporting self-care for eczema for parents/carers and young people.

How to use the Harmonising Outcome Measures for Eczema Core Outcome Set for atopic dermatitis trials: a users’ guide (2023)
Journal Article
Thomas, K. S., Howells, L., Leshem, Y. A., Simpson, E. L., Apfelbacher, C., Spuls, P. I., …Stuart, B. L. (2024). How to use the Harmonising Outcome Measures for Eczema Core Outcome Set for atopic dermatitis trials: a users’ guide. British Journal of Dermatology, 190(4), 527-535. https://doi.org/10.1093/bjd/ljad497

Background The Harmonising Outcome Measures for Eczema (HOME) initiative has agreed upon the Core Outcome Set (COS) for use in atopic dermatitis (AD) clinical trials, but additional guidance is needed to maximize its uptake. Objectives To provid... Read More about How to use the Harmonising Outcome Measures for Eczema Core Outcome Set for atopic dermatitis trials: a users’ guide.

Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation (2023)
Preprint / Working Paper
Abhishek, A., Grainge, M. J., Card, T., Williams, H. C., Taal, M. W., Aithal, G. P., …Riley, R. D. Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation

Background Sulfasalazine induced cytopenia, nephrotoxicity, and hepatotoxicity is uncommon during long-term treatment. Some guidelines recommend three monthly monitoring blood-tests indefinitely while others recommend stopping monitoring after one ye... Read More about Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation.

Ex vivo assessment of basal cell carcinoma surgical margins in Mohs surgery by autofluorescence-Raman spectroscopy: A pilot study (2023)
Journal Article
Boitor, R., Varma, S., Sharma, A., Elsheikh, S., Kulkarni, K., Eldib, K., …Notingher, I. (2024). Ex vivo assessment of basal cell carcinoma surgical margins in Mohs surgery by autofluorescence-Raman spectroscopy: A pilot study. JEADV Clinical Practice, 3(2), 498-507. https://doi.org/10.1002/jvc2.336

Background: Autofluorescence (AF)‐Raman spectroscopy is a technology that can detect tumour tissue in surgically excised skin specimens. The technique does not require tissue fixation, staining, labelling or sectioning, and provides quantitative diag... Read More about Ex vivo assessment of basal cell carcinoma surgical margins in Mohs surgery by autofluorescence-Raman spectroscopy: A pilot study.

Two-week break in methotrexate treatment and COVID-19 vaccine response: a prospective, open label, two-arm parallel-group, multicentre, superiority, randomised controlled trial (2023)
Journal Article
Abhishek, A., Peckham, N., Pade, C., Gibbons, J. M., Cureton, L., Francis, A., …Study investigators, V. (2024). Two-week break in methotrexate treatment and COVID-19 vaccine response: a prospective, open label, two-arm parallel-group, multicentre, superiority, randomised controlled trial. The Lancet Rheumatology, 6(2), E92-E104. https://doi.org/10.1016/S2665-9913%2823%2900298-9

Background Methotrexate is the first-line treatment for immune-mediated inflammatory diseases and reduces vaccine-induced immunity. We evaluated if a 2-week interruption of methotrexate treatment immediately after COVID-19 booster vaccination improv... Read More about Two-week break in methotrexate treatment and COVID-19 vaccine response: a prospective, open label, two-arm parallel-group, multicentre, superiority, randomised controlled trial.

Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial (2023)
Journal Article
Abhishek, A., Peckham, N., Pade, C., Gibbons, J. M., Cureton, L., Francis, A., …Cook, J. A. (2023). Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial. The Lancet Rheumatology, 6(2), e92-e104. https://doi.org/10.1016/s2665-9913%2823%2900298-9

Background: Methotrexate is the first-line treatment for immune-mediated inflammatory diseases and reduces vaccine-induced immunity. We evaluated if a 2-week interruption of methotrexate treatment immediately after COVID-19 booster vaccination improv... Read More about Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial.

Comparison of lotions, creams, gels and ointments for the treatment of childhood eczema: the BEE RCT (2023)
Journal Article
Ridd, M. J., Wells, S., MacNeill, S. J., Sanderson, E., Webb, D., Banks, J., …Santer, M. (2023). Comparison of lotions, creams, gels and ointments for the treatment of childhood eczema: the BEE RCT. Health Technology Assessment, 27(19), 1-120. https://doi.org/10.3310/gzqw6681

Background: Emollients are recommended for children with eczema (atopic eczema/dermatitis). A lack of head-to-head comparisons of the effectiveness and acceptability of the different types of emollients has resulted in a 'trial and error' approach to... Read More about Comparison of lotions, creams, gels and ointments for the treatment of childhood eczema: the BEE RCT.

The long-term safety of topical corticosteroids in atopic dermatitis: A systematic review (2023)
Journal Article
Harvey, J., Lax, S. J., Lowe, A., Santer, M., Lawton, S., Langan, S. M., …Thomas, K. S. (2023). The long-term safety of topical corticosteroids in atopic dermatitis: A systematic review. Skin Health and Disease, 3(5), Article e268. https://doi.org/10.1002/ski2.268

Background: Topical corticosteroids (TCS) are a first-line treatment for eczema, but there are concerns about their safety when used long-term. Objectives: To systematically review adverse effects associated with longer-term use of TCS for eczema. Me... Read More about The long-term safety of topical corticosteroids in atopic dermatitis: A systematic review.

Emollients for preventing atopic eczema: Cost‐effectiveness analysis of the BEEP trial (2023)
Journal Article
Sach, T. H., Lartey, S. T., Davies, C., Chalmers, J. R., Haines, R. H., Bradshaw, L. E., …Williams, H. C. (2023). Emollients for preventing atopic eczema: Cost‐effectiveness analysis of the BEEP trial. Clinical & Experimental Allergy, 53(10), 1011-1019. https://doi.org/10.1111/cea.14381

Background Recent discoveries have led to the suggestion that enhancing skin barrier from birth might prevent eczema and food allergy. Objective To determine the cost‐effectiveness of daily all‐over‐body application of emollient during the firs... Read More about Emollients for preventing atopic eczema: Cost‐effectiveness analysis of the BEEP trial.

The Harmonising Outcome Measures for Eczema (HOME) implementation roadmap (2023)
Journal Article
Leshem, Y. A., Simpson, E., Apfelbacher, C., Spuls, P., Thomas, K. S., Schmitt, J., …Williams, H. C. (2023). The Harmonising Outcome Measures for Eczema (HOME) implementation roadmap. British Journal of Dermatology, 189(6), 710-718. https://doi.org/10.1093/bjd/ljad278

Background Core outcome sets (COS) are consensus-driven sets of minimum outcomes that should be measured and reported in all clinical trials. COS aim to reduce heterogeneity in outcome measurement and reporting, and selective outcome reporting. Imple... Read More about The Harmonising Outcome Measures for Eczema (HOME) implementation roadmap.

Implementation of the HOME core outcome set for clinical trials of atopic eczema—barriers and opportunities: the HOME IX meeting report (2023)
Journal Article
Jacobson, M. E., Thomas, K. S., Apfelbacher, C. J., Leshem, Y. A., Williams, H. C., Gerbens, L. A. A., …On behalf of the Harmonising Outcome Measures for Eczema (HOME) Initiative. (2023). Implementation of the HOME core outcome set for clinical trials of atopic eczema—barriers and opportunities: the HOME IX meeting report. Archives of Dermatological Research, 315, 2617-2622. https://doi.org/10.1007/s00403-023-02647-w

The Harmonising Outcome Measures for Eczema (HOME) initiative established a core outcome set (COS) for atopic eczema (AE) clinical trials in 2019. This set encompasses four core outcome domains and corresponding measurement instruments: clinical sign... Read More about Implementation of the HOME core outcome set for clinical trials of atopic eczema—barriers and opportunities: the HOME IX meeting report.

Is Vaccination Against COVID-19 Associated With Inflammatory Bowel Disease Flare? Self-Controlled Case Series Analysis Using the UK CPRD (2023)
Journal Article
Card, T. R., Nakafero, G., Grainge, M. J., Mallen, C. D., Van-Tam, J. S. N., Williams, H. C., & Abhishek, A. (2023). Is Vaccination Against COVID-19 Associated With Inflammatory Bowel Disease Flare? Self-Controlled Case Series Analysis Using the UK CPRD. American Journal of Gastroenterology, 118(8), 1388-1394. https://doi.org/10.14309/ajg.0000000000002205

INTRODUCTION: To investigate the association between vaccination against coronavirus disease 2019 (COVID-19) and inflammatory bowel disease (IBD) flare. METHODS: Patients with IBD vaccinated against COVID-19 who consulted for disease flare be... Read More about Is Vaccination Against COVID-19 Associated With Inflammatory Bowel Disease Flare? Self-Controlled Case Series Analysis Using the UK CPRD.

Trends in eczema prevalence in children and adolescents: A Global Asthma Network Phase I Study (2023)
Journal Article
Langan, S. M., Mulick, A. R., Rutter, C. E., Silverwood, R., Asher, I., García‐Marcos, L., …Pearce, N. (2023). Trends in eczema prevalence in children and adolescents: A Global Asthma Network Phase I Study. Clinical & Experimental Allergy, 53(3), 337-352. https://doi.org/10.1111/cea.14276

Background: Eczema (atopic dermatitis) is a major global public health issue with high prevalence and morbidity. Our goal was to evaluate eczema prevalence over time, using standardized methodology. Methods: The Global Asthma Network (GAN) Phase I st... Read More about Trends in eczema prevalence in children and adolescents: A Global Asthma Network Phase I Study.

'Eczema shouldn't control you; you should control eczema': qualitative process evaluation of online behavioural interventions to support young people and parents/carers of children with eczema (2022)
Journal Article
Greenwell, K., Sivyer, K., Howells, L., Steele, M., Ridd, M. J., Roberts, A., …Muller, I. (2023). 'Eczema shouldn't control you; you should control eczema': qualitative process evaluation of online behavioural interventions to support young people and parents/carers of children with eczema. British Journal of Dermatology, 188(4), 506-513. https://doi.org/10.1093/bjd/ljac115

Background There is a lack of well-conducted randomized controlled trials evaluating the effectiveness of theory-based online interventions for eczema. To address these deficiencies, we previously developed and demonstrated the effectiveness of two o... Read More about 'Eczema shouldn't control you; you should control eczema': qualitative process evaluation of online behavioural interventions to support young people and parents/carers of children with eczema.

Eczema Care Online behavioural interventions to support self-care for children and young people: two independent, pragmatic, randomised controlled trials (2022)
Journal Article
Santer, M., Muller, I., Becque, T., Stuart, B., Hooper, J., Steele, M., …Thomas, K. S. (2022). Eczema Care Online behavioural interventions to support self-care for children and young people: two independent, pragmatic, randomised controlled trials. BMJ, 379, Article e072007. https://doi.org/10.1136/bmj-2022-072007

Objective: To determine the effectiveness of two online behavioural interventions, one for parents and carers and one for young people, to support eczema self-management. Design: Two independent, pragmatic, parallel group, unmasked, randomised contro... Read More about Eczema Care Online behavioural interventions to support self-care for children and young people: two independent, pragmatic, randomised controlled trials.